Taking on heart disease
At Johnson & Johnson, we have an unrelenting vision to ease the tremendous global burden of cardiovascular diseases, including stroke and atrial fibrillation. Our innovative medical technologies and treatments are addressing some of the most prevalent disorders of the heart and blood vessels, driving better outcomes and lasting impact for patients.
Innovating in Health&Care
-
Shockwave IVL: Inside the development of a game-changing technology to treat coronary and peripheral artery disease
Johnson & Johnson’s Patrick Stephens explains how innovative technology using ultrasonic acoustic pressure waves has made the treatment of certain types of cardiovascular disease easier for doctors and safer for patients. -
Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health
Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 400,000 patients recover from heart injuries.
-
Ask an electrophysiologist: What roles do PFA and RFA play in the treatment of AFib?
Both are types of cardiac ablation, but are distinct in a few key ways. An expert weighs in on when and how they can be harnessed. -
Inside the Ireland facility revolutionizing the way stroke care is approached
Strokes claim millions of lives each year. But innovative research is making treatment more effective and helping neurovascular patients lead longer, fuller lives.
Mapping the course to reducing fluoroscopy in the cath lab
3D mapping systems with 4D imaging. Multi-planar visualization. AI mapping. What do these innovations have in common? They’re all driving down radiation exposure.
“There’s a growing need to expand the CLTI treatment toolbox”
With new innovations, surgeons are able to treat lesions that were, historically, too challenging to cross.
Do you know what heart failure is? (Hint: It’s probably not what you think)
Learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
Inside the all-female coronary interventions trial
EMPOWER CAD is a first-of-its-kind study to determine the effectiveness of IVL in women to address a gender gap in coronary artery disease outcomes—and empower female clinicians along the way.
What is cardiac ablation?
Learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
More from Johnson & Johnson
-
“We are in a golden age of cataract surgery”
Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment. -
Johnson & Johnson named to The Wall Street Journal’s 2026 Best Companies for the Future list
The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list. -
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.
